Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.19 USD | -3.17% |
|
-1.77% | -3.54% |
Capitalization | 7.8B 7.54B 7.09B 6.29B 11.16B 684B 12.45B 85.24B 31.67B 281B 29.23B 28.64B 1,179B | P/E ratio 2024 * |
-12.1x | P/E ratio 2025 * | -10.5x |
---|---|---|---|---|---|
Enterprise value | 6.01B 5.81B 5.46B 4.85B 8.61B 527B 9.6B 65.71B 24.42B 216B 22.53B 22.08B 909B | EV / Sales 2024 * |
17,363x | EV / Sales 2025 * | 4,801x |
Free-Float |
86.7% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Revolution Medicines, Inc.
1 day | -3.17% | ||
1 week | -1.77% | ||
Current month | -1.77% | ||
1 month | -5.02% | ||
3 months | -30.20% | ||
6 months | -1.66% | ||
Current year | -3.54% |







Director | Title | Age | Since |
---|---|---|---|
Mark Goldsmith
CEO | Chief Executive Officer | 63 | 2014-10-31 |
Jack Anders
DFI | Director of Finance/CFO | 48 | 2018-09-30 |
Wei Lin
CTO | Chief Tech/Sci/R&D Officer | 64 | 2023-03-31 |
Manager | Title | Age | Since |
---|---|---|---|
Mark Goldsmith
CHM | Chairman | 63 | - |
Director/Board Member | 67 | 2015-02-28 | |
Alexis Borisy
BRD | Director/Board Member | 53 | 2014-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.16% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-3.17% | -1.77% | +38.60% | +87.10% | 7.8B | ||
-1.50% | +3.75% | +35.87% | -3.30% | 47.96B | ||
-0.87% | +3.37% | -4.61% | -18.56% | 36.65B | ||
-0.77% | -0.06% | +5.00% | +22.20% | 26.22B | ||
-1.27% | -2.82% | -30.53% | -30.59% | 15.97B | ||
-1.71% | -0.99% | +63.75% | +69.66% | 15.52B | ||
-3.01% | -17.30% | -62.70% | -80.13% | 12.55B | ||
-2.93% | -1.01% | +7.15% | -31.33% | 11.51B | ||
-1.90% | +1.42% | +8.49% | +98.15% | 10.98B | ||
+6.11% | +20.16% | - | - | 10.86B | ||
Average | -1.10% | +0.69% | +6.78% | +12.58% | 19.6B | |
Weighted average by Cap. | -1.13% | +1.47% | +10.12% | +3.93% |
2024 * | 2025 * | |
---|---|---|
Net sales | 346K 335K 315K 279K 496K 30.35M 553K 3.78M 1.41M 12.45M 1.3M 1.27M 52.34M | 1.38M 1.34M 1.26M 1.12M 1.98M 121M 2.21M 15.14M 5.62M 49.82M 5.19M 5.09M 209M |
Net income | -581M -562M -528M -469M -832M -50.97B -928M -6.35B -2.36B -20.91B -2.18B -2.13B -87.88B | -711M -688M -646M -573M -1.02B -62.34B -1.14B -7.77B -2.89B -25.58B -2.67B -2.61B -108B |
Net Debt | -1.79B -1.73B -1.62B -1.44B -2.56B -157B -2.85B -19.53B -7.26B -64.26B -6.7B -6.56B -270B | -1.15B -1.11B -1.04B -926M -1.64B -101B -1.83B -12.56B -4.67B -41.32B -4.31B -4.22B -174B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-07 | 42.19 $ | -3.17% | 999,674 |
25-02-06 | 43.57 $ | -1.54% | 1,795,601 |
25-02-05 | 44.25 $ | +4.56% | 1,494,147 |
25-02-04 | 42.32 $ | +0.43% | 844,413 |
25-02-03 | 42.14 $ | -1.89% | 897,150 |
Delayed Quote Nasdaq, February 07, 2025 at 04:00 pm
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RVMD Stock

MarketScreener is also available in this country: United States.
Switch edition